The U.S. Department of Commerce has launched a new application process that could allow pharmaceutical companies to significantly reduce looming Section 232 tariffs if they commit to moving drug manufacturing operations to the United States.

Genentech has announced that the U.S. Food and Drug Administration (FDA) has approved Tecentriq and Tecentriq Hybreza for the adjuvant treatment of adults with muscle-invasive bladder cancer (MIBC) who show circulating tumor DNA molecular residual disease (ctDNA MRD) after bladder removal surgery. The approval marks the first FDA-cleared ctDNA-guided therapy approach for this aggressive cancer type.